Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /data00/vhosts/blog.marketdraft.com/httpdocs/wp-includes/functions.php on line 6121
Regeneron Pharmaceuticals Buys Bankrupt 23andMe for $256 Million - MarketDraft BlogMarketDraft Blog Regeneron Pharmaceuticals Buys Bankrupt 23andMe for $256 Million - MarketDraft Blog

Regeneron Pharmaceuticals Buys Bankrupt 23andMe for $256 Million

Posted in General News by on May 19th, 2025.

Regeneron Pharmaceuticals, a prominent U.S. biotechnology firm, has announced its acquisition of the bankrupt genetic testing company 23andMe for $256 million. This strategic move aims to bolster Regeneron’s capabilities in genetic research and personalized medicine.

Established in 1988 and headquartered in Tarrytown, New York, Regeneron is renowned for its commitment to in-house research and development. The company has developed several FDA-approved medicines, including:

  • Dupixent (dupilumab): Treats conditions like atopic dermatitis and asthma.
  • EYLEA (aflibercept injection): Used for wet age-related macular degeneration and diabetic macular edema.
  • Praluent (alirocumab): Helps lower LDL cholesterol in patients with heart disease.
  • Zaltrap (aflibercept injection): Treats metastatic colorectal cancer.

Regeneron’s innovative approach has positioned it as a leader in addressing serious medical conditions across various therapeutic areas.

23andMe, once valued at nearly $6 billion, filed for Chapter 11 bankruptcy in March 2025 after facing financial challenges, including a significant data breach in 2023 that affected approximately 7 million users. Regeneron’s acquisition includes 23andMe’s consumer DNA testing services and its extensive biobank containing anonymized genetic data from over 15 million customers.

By integrating 23andMe’s vast genetic database with its existing research, Regeneron aims to accelerate the identification of genetic factors in diseases and the development of targeted therapies. This move is expected to enhance Regeneron’s drug discovery and development processes.

Post-acquisition, 23andMe will continue to operate its consumer genetics services under Regeneron’s ownership. The company has committed to maintaining 23andMe’s existing privacy policies and data protection standards. An independent consumer privacy ombudsman will assess the deal’s impact on user privacy, with findings to be presented to the court by June 10.

However, the acquisition does not include 23andMe’s telehealth subsidiary, Lemonaid Health, which will be shut down.

The public response to the acquisition has been mixed. While some view it as a strategic move that validates 23andMe’s vision of personalized healthcare, others express concerns about data privacy and the ethical use of genetic information.

In the stock market, 23andMe’s shares experienced a significant increase following the announcement, doubling in value. However, they remain down approximately 99% from their peak after the company’s IPO. Regeneron’s stock has shown stability, reflecting investor confidence in the company’s strategic direction.

LetsEncrypt SSL Secure Stripe Payment Processing